Priced like an automaker, sputtering Gilead shares lure value bets

NEW YORK (Reuters) - Shares of Gilead Sciences Inc are languishing over concerns about the U.S. biotechnology company's declining hepatitis C drugs and profit outlook, but some value investors sense an opportunity with shares at extremely cheap levels.